The right-to-try bills passed by Congress would remove FDA’s expanded access mandate and leave patients at greater risk, said Arthur Caplan, the Drs. William F. and Virginia Connolly Mitty Professor and founding director of the Division of Medical Ethics at the New York University School of Medicine.
While doing somewhat-routine reporting on this year’s Senate Appropriations Committee bills, Paul Goldberg, editor and publisher of The Cancer Letter, quickly realized that he was seeing a full bipartisan rejection of President Donald J. Trump’s plan to defund and therefore dismantle biomedical research in the United States.
